Loading
Anxiety / Cancer / Depression · Phase 2 Trial
ClinicalTrials.gov · August 12, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 clinical trial registration for psilocybin-assisted psychotherapy in cancer survivors with depression and/or anxiety, currently recruiting participants. No efficacy or safety results are available in this registry record; the study is designed to evaluate feasibility, safety, and adverse events over approximately one year of follow-up.
Phase 2, Interventional, Single Group, Open label, Supportive Care purpose. Depression, Anxiety, Cancer; age from 18 Years. Intervention: Treatment with Psilocybin. n = 20. 1 site: United States.
This is a Phase 2 clinical trial registration for psilocybin-assisted psychotherapy in cancer survivors with depression and/or anxiety, currently recruiting participants. No efficacy or safety results are available in this registry record; the study is designed to evaluate feasibility, safety, and adverse events over approximately one year of follow-up.
No efficacy endpoints specified; primary focus is feasibility and safety.
Clinicians should recognize this as an active early-phase feasibility and safety study; no clinical guidance can be drawn from this registry record alone. Results, when published, will inform whether psilocybin-assisted psychotherapy is safe and feasible in this vulnerable population, but efficacy remains unstudied in this trial.
Early-phase interventional study (Phase 2) with small planned enrollment (n=20) assessing feasibility and safety of a novel psychedelic intervention in a specific population; results not yet reported.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize this as an active early-phase feasibility and safety study; no clinical guidance can be drawn from this registry record alone. Results, when published, will inform whether psilocybin-assisted psychotherapy is safe and feasible in this vulnerable population, but efficacy remains unstudied in this trial.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06801041). This is a study registration, not published results. Lead sponsor: M.D. Anderson Cancer Center. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 20 participants (ESTIMATED). Conditions: Depression, Anxiety, Cancer. Interventions: DRUG: Psilocybin. Primary outcome measures: Safety and Adverse Events (AEs) , Through study completion; an average of 1 year. Brief summary: This clinical research study is to learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy for cancer survivors with depression and/or anxiety.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.